Marina Posts Lower Q2 Loss, Faces Cash Crunch by Year End | GenomeWeb

Marina Biotech last week reported a lower second-quarter net loss as research and development spending dropped and revenues increased.

The company also disclosed in a filing with the US Securities and Exchange Commission that its current resources are not sufficient to fund operations through the year and that it will need to raise money before then or revamp its drug-development plans.

For the three-month period ended June 30, Marina's net loss fell to $3.6 million, or $0.08 per share, versus a year-ago loss of $4.1 million, or $0.34 per share.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.